InsiderSource
TRDA

Entrada Therapeutics, Inc.

SEC CIK 1689375
$6.58 −34.7% · 90 days
90-day buys
$29.3K
1 open-market
90-day sells
$661.1K
3 open-market
Net insider flow
−$631.8K
Net selling
Filings shown
98
Most recent
Advertisement

At a glance

Over the last 90 days, insiders at TRDA have sold a net $631.8K of stock (1 open-market buy vs 3 sells).

Largest recent trade: Mpm Bioventures 2018, L.p., TRDA's 10% owner, spent $2M of their own money on 100,000 shares at $20, growing their stake 2%.

Most active filer: Wentworth Kory James, with 40 transactions among the recent filings shown.

Insider transaction history

Form 4 filings for TRDA, newest first
View on SEC EDGAR ↗
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Mar 19, 2025 ΔOwn −1.6%

Wentworth Kory James sold $19K of TRDA, trimming their stake 2%.

−$19K
1,784 sh @ $11
Advertisement
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 3, 2024 ΔOwn −6.3%

Wentworth Kory James sold $100K of TRDA, trimming their stake 6%.

−$100K
5,000 sh @ $20
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Nov 13, 2024 ΔOwn −10%

Wentworth Kory James sold $172.6K of TRDA, trimming their stake 10%.

−$172.6K
8,637 sh @ $20
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Sep 10, 2024 ΔOwn −4.0%

Wentworth Kory James sold $47.8K of TRDA, trimming their stake 4%.

−$47.8K
3,195 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Jul 10, 2024 ΔOwn −2.1%

Wentworth Kory James sold $26.3K of TRDA, trimming their stake 2%.

−$26.3K
1,758 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Mar 8, 2024 ΔOwn −5.2%

Wentworth Kory James sold $50.3K of TRDA, trimming their stake 5%.

−$50.3K
4,086 sh @ $12
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 26, 2023 ΔOwn −11%

Wentworth Kory James sold $99.5K of TRDA, trimming their stake 11%.

−$99.5K
6,529 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 26, 2023 ΔOwn −6.9%

Wentworth Kory James sold $60.6K of TRDA, trimming their stake 7%.

−$60.6K
3,677 sh @ $16
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 26, 2023 ΔOwn −4.2%

Wentworth Kory James sold $33.2K of TRDA, trimming their stake 4%.

−$33.2K
2,200 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Sep 6, 2023 ΔOwn −1.8%

Wentworth Kory James sold $12.2K of TRDA, trimming their stake 2%.

−$12.2K
904 sh @ $13
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Jul 12, 2023 ΔOwn −9.6%

Wentworth Kory James sold $69.9K of TRDA, trimming their stake 10%.

−$69.9K
3,884 sh @ $18
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Jul 12, 2023 ΔOwn −14%

Wentworth Kory James sold $110K of TRDA, trimming their stake 14%.

−$110K
6,116 sh @ $18
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Jun 23, 2023 ΔOwn −19%

Wentworth Kory James sold $127.5K of TRDA, trimming their stake 19%.

−$127.5K
8,593 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Jun 23, 2023 ΔOwn −24%

Wentworth Kory James sold $135.1K of TRDA, trimming their stake 24%.

−$135.1K
8,907 sh @ $15
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Mar 3, 2023 ΔOwn −3.6%

Wentworth Kory James sold $16.8K of TRDA, trimming their stake 4%.

−$16.8K
1,602 sh @ $10
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 12, 2022 ΔOwn −22%

Wentworth Kory James sold $86.2K of TRDA, trimming their stake 22%.

−$86.2K
4,550 sh @ $19
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Dec 6, 2022 ΔOwn −15%

Wentworth Kory James sold $52.9K of TRDA, trimming their stake 15%.

−$52.9K
2,910 sh @ $18
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Nov 18, 2022 ΔOwn −1.2%

Wentworth Kory James sold $3.6K of TRDA, trimming their stake 1%.

−$3.6K
200 sh @ $18
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Aug 26, 2022 ΔOwn −12%

Wentworth Kory James sold $22K of TRDA, trimming their stake 12%.

−$22K
1,551 sh @ $14
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Aug 26, 2022 ΔOwn −18%

Wentworth Kory James sold $38.1K of TRDA, trimming their stake 18%.

−$38.1K
2,817 sh @ $14
TRDA
Entrada Therapeutics, Inc.
Sell WENTWORTH KORY JAMES · Chief Financial Officer · Open-market sale · filed Aug 26, 2022 ΔOwn −2.3%

Wentworth Kory James sold $4.3K of TRDA, trimming their stake 2%.

−$4.3K
301 sh @ $14
Advertisement

About TRDA insider activity

This page tracks every recent Form 4 filed for Entrada Therapeutics, Inc. with the U.S. Securities and Exchange Commission. Form 4 is the disclosure that company insiders — officers, directors, and holders of more than 10% of the stock — must file within two business days of buying or selling shares.

The summary above nets open-market purchases against open-market sales over the trailing 90 days. Open-market trades (codes P and S) tend to carry the most signal because they reflect a deliberate choice to put money in or take it out, as opposed to routine grants, option exercises, or tax-withholding events. Use the badges on each row to tell them apart, and always confirm details against the original filing before drawing conclusions.

Frequently asked questions

How often is TRDA insider data updated?

Continuously. We read from SEC EDGAR, so new Form 4 filings for Entrada Therapeutics, Inc. usually appear here within minutes of being accepted by the SEC.

What does "net insider flow" mean?

It is the total dollar value of open-market insider purchases minus open-market sales over the last 90 days. A positive number (green) means insiders bought more than they sold; a negative number (red) means the reverse.

Why do some rows show grants or option exercises instead of buys?

Insiders receive stock through compensation as well as buying it outright. Form 4 captures all of these. We label each transaction by its SEC code so you can focus on open-market activity if you prefer.

Is this investment advice?

No. InsiderSource presents public filing data for informational purposes only. Insider activity is one of many factors to consider and is never a recommendation to buy or sell.